Inmune Bio, Inc. Forecast, price target & analysts
Inmune Bio, Inc. Target price 2025 - Analyst rating & recommendation
Inmune Bio, Inc. Classifications & Recommendation:
Inmune Bio, Inc. Price Target
| Target Price | $7.14 |
| Price | $1.51 |
| Potential |
372.85%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target Inmune Bio, Inc. 2026 .
The average Inmune Bio, Inc. target price is $7.14.
This is
372.85%
register free of charge
$22.05
1,360.26%
register free of charge
$2.02
33.77%
register free of charge
|
|
| A rating was issued by 12 analysts: 8 Analysts recommend Inmune Bio, Inc. to buy, 4 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Inmune Bio, Inc. stock has an average upside potential 2026 of
372.85%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.01 | 0.04 |
| 93.75% | 308.00% | |
| Net Margin | -420,800.00% | -103,302.15% |
| 2,143.52% | 75.45% |
8 Analysts have issued a sales forecast Inmune Bio, Inc. 2025 . The average Inmune Bio, Inc. sales estimate is
This results in the following potential growth metrics:
8 Inmune Bio, Inc. Analysts have issued a net profit forecast 2025. The average Inmune Bio, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.11 | -1.59 |
| 26.35% | 24.64% | |
| P/E | negative | |
| EV/Sales | 304.17 |
8 Analysts have issued a Inmune Bio, Inc. forecast for earnings per share. The average Inmune Bio, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Inmune Bio, Inc....
Current Inmune Bio, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Maxim Group |
Locked
➜
Locked
|
Locked | Jul 02 2025 |
| BTIG |
Locked
➜
Locked
|
Locked | Jul 01 2025 |
| Scotiabank |
Locked
➜
Locked
|
Locked | Jul 01 2025 |
| Maxim Group |
Locked
➜
Locked
|
Locked | Feb 13 2025 |
| Scotiabank |
Locked
➜
Locked
|
Locked | Feb 11 2025 |
| Alliance Global Partners |
Locked
➜
Locked
|
Locked | Oct 21 2024 |
| Raymond James |
Locked
➜
Locked
|
Locked | Sep 27 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Maxim Group:
Locked
➜
Locked
|
Jul 02 2025 |
|
Locked
BTIG:
Locked
➜
Locked
|
Jul 01 2025 |
|
Locked
Scotiabank:
Locked
➜
Locked
|
Jul 01 2025 |
|
Locked
Maxim Group:
Locked
➜
Locked
|
Feb 13 2025 |
|
Locked
Scotiabank:
Locked
➜
Locked
|
Feb 11 2025 |
|
Locked
Alliance Global Partners:
Locked
➜
Locked
|
Oct 21 2024 |
|
Locked
Raymond James:
Locked
➜
Locked
|
Sep 27 2024 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
